Stay updated on Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Sign up to get notified when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.

Latest updates to the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page
- ChecktodayChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed in the site’s release notes.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This is a metadata/display change and does not affect study information or functionality.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedAdded a new publication citation: Avapritinib improves cutaneous involvement in indolent systemic mastocytosis from the PIONEER study (J Am Acad Dermatol, online ahead of print).SummaryDifference0.0%

- Check36 days agoChange DetectedNew revision tag updated from v3.4.1 to v3.4.2; no other content changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check43 days agoChange Detected- Revision: v3.4.1 replaces v3.4.0 on the page.SummaryDifference0.0%

- Check58 days agoChange DetectedAdded a glossary display and updated metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0). Some labels were removed or changed (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

Stay in the know with updates to Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.